

# RESOLUTION OF THE CITY COUNCIL

No. 249

Approved May 21, 2025

WHEREAS, 340B entities statewide, such as hospitals or clinics, are vulnerable to deliberate underpayment, network restriction or exclusion, and discriminatory terms for reimbursement by or services provided by health insurers, pharmacy benefit managers, and other agents when providing deeply discounted prescription drugs; and

WHEREAS, Cherished healthcare institutions serving Providence, including Providence Community Health Centers, CODAC, Women & Infants Hospital, and Rhode Island Hospital, are subject to underpayment and thus to financial shortfalls that jeopardize the quality of care they strive daily to provide; and

WHEREAS, The most vulnerable residents of Providence are deeply impacted by the arbitrary impediments to medical care created by this conduct, with limits to access and quality of care imposed by non-providers for the sake of profit; and

WHEREAS, If enacted, House Bill 5634 and its Senate companion Senate Bill 114 would prohibit discriminatory conduct by health insurers, pharmacy benefit managers, pharmaceutical companies, and other payors and agents in reimbursements to 340B entities for prescription drugs covered in the 340B program, including lower reimbursements than those provided to non-340B entities for the same drug, differential terms for 340B entities that include fees or charges or clawbacks or other adjustments, lower dispensing fees than those for non-340B entities, restrictions on pharmacy network usage, and interference that prevents patients from choosing a 340B entity to dispense drugs; and

WHEREAS, Hospitals and clinics both in Providence and statewide will be able to avoid compromises in patient care born of needless financial difficulty; and



WHEREAS, Residents citywide receiving lifesaving drugs from 340B participants will benefit from more consistent and widespread access to vital medication; and

WHEREAS, The Providence City Council wishes to convey its gratitude to the Rhode Island General Assembly for its leadership in this matter of great concern.

NOW, THEREFORE, BE IT RESOLVED, That the Providence City Council strongly supports H-5634 and its Senate companion S-0114 and urges the General Assembly to pass this legislation necessary for the affordability and efficacy of healthcare in Rhode Island; and

BE IT FURTHER RESOLVED, That upon passage, copies of this resolution be transmitted to lead sponsors Representative Jon Brien and Senator Bridget Valverde, Speaker of the Rhode Island House of Representatives K. Joseph Shekarchi, President of the Rhode Island Senate Valarie J. Lawson, and the members of the Providence Delegation.

IN CITY COUNCIL  
MAY 15 2025  
READ AND PASSED

  
RACHEL M. MILLER, PRESIDENT  
  
CLERK

I HEREBY APPROVE.

  
Mayor

Date: 5/21/25

2025 -- H 5634

LC000919

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2025

A N A C T

RELATING TO BUSINESSES AND PROFESSIONS -- DEFENDING AFFORDABLE  
PRESCRIPTION DRUG COSTS ACT

Introduced By: Representatives J. Brien, Baginski, Cotter, Hopkins, and Place

Date Introduced: February 26, 2025

Referred To: House Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Title 5 of the General Laws entitled "BUSINESSES AND PROFESSIONS"

2 is hereby amended by adding thereto the following chapter:

3 CHAPTER 19.3

4 DEFENDING AFFORDABLE PRESCRIPTION DRUG COSTS ACT

5 **5-19.3-1. Short title.**

6 This chapter shall be known and may be cited as the "Defending Affordable Prescription  
7 Drug Costs Act".

8 **5-19.3-2. Definitions.**

9 As used in this chapter, the following terms have the following meanings:

10 (1) "340B drug" means a drug that has been subject to any offer for reduced prices by a  
11 manufacturer pursuant to 42 U.S.C. § 256b and is purchased by a covered entity as defined in 42  
12 U.S.C. § 256b(a)(4).

13 (2) "340B entity" means an entity participating or authorized to participate in the federal  
14 340B drug discount program, as described in 42 U.S.C. § 256b, including its pharmacy, or any  
15 pharmacy contracted with the participating entity to dispense drugs purchased through the 340B  
16 drug discount program.

17 (3) "Health insurer" means every nonprofit medical service corporation, hospital service  
18 corporation, health maintenance organization, or other insurer offering or insuring health services;

1 the term shall, in addition, include any entity defined as an “insurer” under § 42-62-4 and any third-  
2 party administrator when interacting with health care providers and enrollees on behalf of the  
3 insurer.

4 (4) "Pharmaceutical manufacturer" means a person that manufactures a prescription drug  
5 and sells, directly or through another person, the prescription drug for distribution in this state.

6 (5) "Pharmacy" has the meaning set forth in § 5-19.1-2.

7 (6) "Pharmacy benefit manager (PBMs)" means a person or entity employed by for-profit  
8 companies that manage prescription drug benefits on behalf of private insurers, Medicare Part D  
9 drug plans, government employee plans, large employers, and Medicaid managed care  
10 organizations (MCOs).

11 (7) "Rebate(s)" means all price concessions paid by a manufacturer or any other third party  
12 to PBMs including rebates, discounts, credits, fees, manufacturer administrative fees, or other  
13 payments that are based on actual or estimated utilization of a covered drug or price concessions  
14 based on the effectiveness of a covered drug.

15 **5-19.3-3. Prohibition of certain discriminatory actions related to reimbursement of**  
16 **340B entities.**

17 (a) With respect to reimbursement to a 340B entity for 340B drugs, a health insurer,  
18 pharmacy benefit manager, other third-party payor, or its agent shall not do any of the following:

19 (1) Reimburse a 340B entity for 340B drugs at a rate lower than that paid for the same drug  
20 to entities that are not 340B entities or lower reimbursement for a claim on the basis that the claim  
21 is for a 340B drug.

22 (2) Impose any terms or conditions on any 340B entity with respect to any of the following  
23 that differ from such terms or conditions applied to non-340B entities on the basis that the entity  
24 participates in the federal 340B drug discount program set forth in 42 U.S.C. § 256b or that a drug  
25 is a 340B drug including, without limitation, any of the following:

26 (i) Fees, charges, clawbacks, or other adjustments or assessments. For purposes of this  
27 section, the term "other adjustment" includes placing any additional requirements, restrictions, or  
28 unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B  
29 entity that are not placed upon other entities that do not participate in the 340B drug discount  
30 program, including affiliate pharmacies of the health insurer, pharmacy benefit manager, or other  
31 third-party payor.

32 (ii) Dispensing fees that are less than the dispensing fees for non-340B entities.

33 (iii) Restrictions or requirements regarding participation in standard or preferred pharmacy  
34 networks.

1 (iv) Requirements relating to the frequency or scope of audits of inventory management  
2 systems.

3 (v) Requirements that a claim for a drug include any identification, billing modifier,  
4 attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted  
5 unless it is required by the Centers for Medicare and Medicaid Services or the Medicaid program.

6 (vi) Any other restrictions, conditions, practices, or policies that are not imposed on non-  
7 340B entities.

8 (3) Require a 340B entity to reverse, resubmit, or clarify a claim after the initial  
9 adjudication unless these actions are in the normal course of pharmacy business and not related to  
10 340B drug pricing.

11 (4) Discriminate against a 340B entity in a manner that prevents or interferes with any  
12 patient's choice to receive such drugs from the 340B entity, including the administration of such  
13 drugs. For purposes of this section, it is considered a discriminatory practice that prevents or  
14 interferes with a patient's choice to receive drugs at a 340B entity if a health insurer, pharmacy  
15 benefit manager, or other third-party payor places any additional requirements, restrictions, or  
16 unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B  
17 entity including, but not limited to, requiring a claim for a drug to include any identification, billing  
18 modifier, attestation or other indication that a drug is a 340B drug in order to be processed or  
19 resubmitted unless it is required by the centers for Medicare and Medicaid services or the executive  
20 office of health and human services in administration of the Medicaid program.

21 (5) Include any other provision in a contract between a health insurer, pharmacy benefit  
22 manager, or other third-party payor and a 340B entity that discriminates against the 340B entity or  
23 prevents or interferes with an individual's choice to receive a prescription drug from a 340B entity,  
24 including the administration of the drug, in person or via direct delivery, mail, or other form of  
25 shipment, or creation of a restriction or additional charge on a patient who chooses to receive drugs  
26 from a 340B entity.

27 (6) Require or compel the submission of ingredient costs or pricing data pertaining to 340B  
28 drugs to any health insurer, pharmacy benefit manager, or other third-party payor.

29 (7) Exclude any 340B entity from the health insurer, pharmacy benefit manager, or other  
30 third-party payor network or refusing to contract with a 340B entity for reasons other than those  
31 that apply equally to non-340B entities.

32 **5-19.3-4. Exclusion.**

33 Nothing in this chapter applies to the Medicaid program as payor when Medicaid provides  
34 reimbursement for covered outpatient drugs as defined in 42 U.S.C. § 1396r-8(k).

1           **5-19.3-5. Prohibition on certain discriminatory actions by a pharmaceutical**  
2 **manufacturer, agent, or affiliate of such manufacturer related to 340B entities.**

3           (a) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not deny,  
4 restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B  
5 drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is  
6 authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity  
7 unless such receipt is prohibited by the United States department of health and human services.

8           (b) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not  
9 interfere with a pharmacy contracted with a 340B entity.

10           **5-19.3-6. Violations.**

11           (a) The commission of any act prohibited by this chapter is considered a violation of the  
12 Rhode Island deceptive trade practices act set forth in chapter 13.1 of title 6, as may be amended  
13 from time to time, and subject to any penalties hereunder; provided, however, that there shall be no  
14 right to bring a private or class action pursuant to such chapter 13.1 of title 6.

15           (b) A violation of chapter 13.1 of title 6 ("deceptive trade practices") shall occur each time  
16 a prohibited act is committed.

17           **5-19.3-7. Federal preemption.**

18           (a) Nothing in this chapter is to be construed or applied to be less restrictive than federal  
19 law for a person or entity regulated by this chapter.

20           (b) Nothing in this chapter is to be construed or applied to be in conflict with any of the  
21 following:

22               (1) Applicable federal law and related regulations.

23               (2) Other laws of this state if the state law is compatible with applicable federal law.

24           (c) Limited distribution of a drug required under 21 U.S.C. § 355-1 is not to be construed  
25 as a violation of this chapter.

26           SECTION 2. This act shall take effect upon passage.

=====  
LC000919  
=====

EXPLANATION  
BY THE LEGISLATIVE COUNCIL  
OF  
A N A C T  
RELATING TO BUSINESSES AND PROFESSIONS -- DEFENDING AFFORDABLE  
PRESCRIPTION DRUG COSTS ACT

\*\*\*

1           This act would prohibit any health insurer, pharmacy benefit manager, or other third-party  
2    payor from discriminating against any 340B entity participating in a drug discount program. This  
3    act would further prohibit a pharmaceutical manufacturer or wholesaler from denying, restricting,  
4    prohibiting or otherwise interfering, directly or indirectly, with any contract to dispense or receive  
5    340B drugs. Violation of the provisions of this act would be considered a violation of chapter 13.1  
6    of title 6 ("deceptive trade practices").

7           This act would take effect upon passage.

=====  
LC000919  
=====

2025 -- S 0114

=====  
LC000843  
=====

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2025

—————  
A N A C T

RELATING TO BUSINESSES AND PROFESSIONS -- DEFENDING AFFORDABLE  
PRESCRIPTION DRUG COSTS ACT

Introduced By: Senators Valverde, DiMario, Ujifusa, Pearson, Murray, Bell, Euer, and  
Lauria

Date Introduced: January 31, 2025

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Title 5 of the General Laws entitled "BUSINESSES AND PROFESSIONS"

2 is hereby amended by adding thereto the following chapter:

3 CHAPTER 19.3

4 DEFENDING AFFORDABLE PRESCRIPTION DRUG COSTS ACT

5 **5-19.3-1. Short title.**

6 This chapter shall be known and may be cited as the "Defending Affordable Prescription  
7 Drug Costs Act".

8 **5-19.3-2. Definitions.**

9 As used in this chapter, the following terms have the following meanings:

10 (1) "340B drug" means a drug that has been subject to any offer for reduced prices by a  
11 manufacturer pursuant to 42 U.S.C. § 256b and is purchased by a covered entity as defined in 42  
12 U.S.C. § 256b(a)(4).

13 (2) "340B entity" means an entity participating or authorized to participate in the federal  
14 340B drug discount program, as described in 42 U.S.C. § 256b, including its pharmacy, or any  
15 pharmacy contracted with the participating entity to dispense drugs purchased through the 340B  
16 drug discount program.

17 (3) "Health insurer" means every nonprofit medical service corporation, hospital service  
18 corporation, health maintenance organization, or other insurer offering or insuring health services;

1 the term shall, in addition, include any entity defined as an “insurer” under § 42-62-4 and any third-  
2 party administrator when interacting with health care providers and enrollees on behalf of the  
3 insurer.

4 (4) "Pharmaceutical manufacturer" means a person that manufactures a prescription drug  
5 and sells, directly or through another person, the prescription drug for distribution in this state.

6 (5) "Pharmacy" has the meaning set forth in § 5-19.1-2.

7 (6) "Pharmacy benefit manager (PBMs)" means a person or entity employed by for-profit  
8 companies that manage prescription drug benefits on behalf of private insurers, Medicare Part D  
9 drug plans, government employee plans, large employers, and Medicaid managed care  
10 organizations (MCOs).

11 (7) "Rebate(s)" means all price concessions paid by a manufacturer or any other third party  
12 to PBMs including rebates, discounts, credits, fees, manufacturer administrative fees, or other  
13 payments that are based on actual or estimated utilization of a covered drug or price concessions  
14 based on the effectiveness of a covered drug.

15 **5-19.3-3. Prohibition of certain discriminatory actions related to reimbursement of**  
16 **340B entities.**

17 (a) With respect to reimbursement to a 340B entity for 340B drugs, a health insurer,  
18 pharmacy benefit manager, other third-party payor, or its agent shall not do any of the following:

19 (1) Reimburse a 340B entity for 340B drugs at a rate lower than that paid for the same drug  
20 to entities that are not 340B entities or lower reimbursement for a claim on the basis that the claim  
21 is for a 340B drug.

22 (2) Impose any terms or conditions on any 340B entity with respect to any of the following  
23 that differ from such terms or conditions applied to non-340B entities on the basis that the entity  
24 participates in the federal 340B drug discount program set forth in 42 U.S.C. § 256b or that a drug  
25 is a 340B drug including, without limitation, any of the following:

26 (i) Fees, charges, clawbacks, or other adjustments or assessments. For purposes of this  
27 section, the term "other adjustment" includes placing any additional requirements, restrictions, or  
28 unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B  
29 entity that are not placed upon other entities that do not participate in the 340B drug discount  
30 program, including affiliate pharmacies of the health insurer, pharmacy benefit manager, or other  
31 third-party payor.

32 (ii) Dispensing fees that are less than the dispensing fees for non-340B entities.

33 (iii) Restrictions or requirements regarding participation in standard or preferred pharmacy  
34 networks.

1 (iv) Requirements relating to the frequency or scope of audits of inventory management  
2 systems.

3 (v) Requirements that a claim for a drug include any identification, billing modifier,  
4 attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted  
5 unless it is required by the Centers for Medicare and Medicaid Services or the Medicaid program.

6 (vi) Any other restrictions, conditions, practices, or policies that are not imposed on non-  
7 340B entities.

8 (3) Require a 340B entity to reverse, resubmit, or clarify a claim after the initial  
9 adjudication unless these actions are in the normal course of pharmacy business and not related to  
10 340B drug pricing.

11 (4) Discriminate against a 340B entity in a manner that prevents or interferes with any  
12 patient's choice to receive such drugs from the 340B entity, including the administration of such  
13 drugs. For purposes of this section, it is considered a discriminatory practice that prevents or  
14 interferes with a patient's choice to receive drugs at a 340B entity if a health insurer, pharmacy  
15 benefit manager, or other third-party payor places any additional requirements, restrictions, or  
16 unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B  
17 entity including, but not limited to, requiring a claim for a drug to include any identification, billing  
18 modifier, attestation or other indication that a drug is a 340B drug in order to be processed or  
19 resubmitted unless it is required by the centers for Medicare and Medicaid services or the executive  
20 office of health and human services in administration of the Medicaid program.

21 (5) Include any other provision in a contract between a health insurer, pharmacy benefit  
22 manager, or other third-party payor and a 340B entity that discriminates against the 340B entity or  
23 prevents or interferes with an individual's choice to receive a prescription drug from a 340B entity,  
24 including the administration of the drug, in person or via direct delivery, mail, or other form of  
25 shipment, or creation of a restriction or additional charge on a patient who chooses to receive drugs  
26 from a 340B entity.

27 (6) Require or compel the submission of ingredient costs or pricing data pertaining to 340B  
28 drugs to any health insurer, pharmacy benefit manager, or other third-party payor.

29 (7) Exclude any 340B entity from the health insurer, pharmacy benefit manager, or other  
30 third-party payor network or refusing to contract with a 340B entity for reasons other than those  
31 that apply equally to non-340B entities.

32 **5-19.3-4. Exclusion.**

33 Nothing in this chapter applies to the Medicaid program as payor when Medicaid provides  
34 reimbursement for covered outpatient drugs as defined in 42 U.S.C. § 1396r-8(k).

1           **5-19.3-5. Prohibition on certain discriminatory actions by a pharmaceutical**  
2 **manufacturer, agent, or affiliate of such manufacturer related to 340B entities.**

3           (a) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not deny,  
4 restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B  
5 drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is  
6 authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity  
7 unless such receipt is prohibited by the United States department of health and human services.

8           (b) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not  
9 interfere with a pharmacy contracted with a 340B entity.

10           **5-19.3-6. Violations.**

11           (a) The commission of any act prohibited by this chapter is considered a violation of the  
12 Rhode Island deceptive trade practices act set forth in chapter 13.1 of title 6, as may be amended  
13 from time to time, and subject to any penalties hereunder; provided, however, that there shall be no  
14 right to bring a private or class action pursuant to such chapter 13.1 of title 6.

15           (b) A violation of chapter 13.1 of title 6 ("deceptive trade practices") shall occur each time  
16 a prohibited act is committed.

17           **5-19.3-7. Federal preemption.**

18           (a) Nothing in this chapter is to be construed or applied to be less restrictive than federal  
19 law for a person or entity regulated by this chapter.

20           (b) Nothing in this chapter is to be construed or applied to be in conflict with any of the  
21 following:

22           (1) Applicable federal law and related regulations.

23           (2) Other laws of this state if the state law is compatible with applicable federal law.

24           (c) Limited distribution of a drug required under 21 U.S.C. § 355-1 is not to be construed  
25 as a violation of this chapter.

26           SECTION 2. This act shall take effect upon passage.

=====  
LC000843  
=====

EXPLANATION  
BY THE LEGISLATIVE COUNCIL  
OF  
A N A C T  
RELATING TO BUSINESSES AND PROFESSIONS -- DEFENDING AFFORDABLE  
PRESCRIPTION DRUG COSTS ACT

\*\*\*

1           This act would prohibit any health insurer, pharmacy benefit manager, or other third-party  
2    payor from discriminating against any 340B entity participating in a drug discount program. This  
3    act would further prohibit a pharmaceutical manufacturer or wholesaler from denying, restricting,  
4    prohibiting or otherwise interfering, directly or indirectly, with any contract to dispense or receive  
5    340B drugs. Violation of the provisions of this act would be considered a violation of chapter 13.1  
6    of title 6 ("deceptive trade practices").

7           This act would take effect upon passage.

=====  
LC000843  
=====